2 documents found, page 1 of 1
Outcomes of cerebral venous thrombosis due to vaccine-induced immune thrombotic...
van de Munckhof, Anita; Lindgren, Erik; Kleinig, Timothy J.; Field, Thalia S.; Cordonnier, Charlotte; Krzywicka, Katarzyna; Poli, SvenBackground: Cerebral venous thrombosis (CVT) due to vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe condition, with high in-hospital mortality rates. Here, we report clinical outcomes of patients with CVT-VITT after SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination who survived initial hospitalization. Methods: We used data from an international registry of patients ...
The benefit of EXtending oral antiCOAgulation treatment EXCOA after acute cereb...
Miranda, Bruno; Aaron, Sanjith; Arauz, Antonio; Barinagarrementeria, Fernando; Borhani-Haghighi, Afshin; Carvalho, Marta; Conforto, Adriana B.Rationale: After a cerebral vein thrombosis, there is an increased risk of further venous thromboembolic events. The optimal duration of anticoagulation after cerebral vein thrombosis is unknown. Aim: To compare efficacy and safety of a policy of short- (3–6 months) versus long-term (12 months) anticoagulation (any type venous thromboembolic events) after cerebral vein thrombosis for the prevention of venous th...